Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study
Obesity has emerged as a global pandemic, with its prevalence notably increasing during the COVID-19 lockdown of 2019. In response, many individuals have turned to pharmacological interventions, including antidiabetic medications, as means of achieving weight loss with minimal effort. This study aim...
Gespeichert in:
| Veröffentlicht in: | PloS one 2024-12, Vol.19 (12), p.e0314407 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | e0314407 |
| container_title | PloS one |
| container_volume | 19 |
| creator | Abutaima, Rana Barakat, Muna Sawan, Hana M Al Omari, Shatha M Mhaidat, Nizar M |
| description | Obesity has emerged as a global pandemic, with its prevalence notably increasing during the COVID-19 lockdown of 2019. In response, many individuals have turned to pharmacological interventions, including antidiabetic medications, as means of achieving weight loss with minimal effort. This study aims to assess the knowledge, attitudes, and practices of the Jordanian population regarding the use of antidiabetic agents, specifically glucagon-like peptide-1 receptor agonists and biguanides, for weight management.
A self-administered validated online questionnaire was developed and disseminated to public utilizing a cross-sectional design. Data were extracted to examine descriptive statistics. Linear regression was performed to evaluate associations with knowledge and attitude. A p-value ≤0.05 was chosen to indicate statistical significance.
Total of 389 responses were analyzed, 65.6% females, 54.2% married, 78.1% living in the center of Jordan, 35.5% overweight and 26.5% have >1000 Jordanian Dinars monthly income. Fifty seven percent of the study participants think that antidiabetics could be used for weight loss. 47.27%, 44.55%, 68.18% recognized glucagon-like peptide-1receptor agonists; (Ozempic®), (Saxenda®), (Mounjaro®) as well as (Glucophage®) use for weight loss, respectively and 12.3% of participants used medications to lose weight. Neutral attitude was observed. Gender and body mass index were significantly affecting the participants knowledge (p |
| doi_str_mv | 10.1371/journal.pone.0314407 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3141380487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A819044063</galeid><doaj_id>oai_doaj_org_article_7b4718de214445d39244ab10adc453aa</doaj_id><sourcerecordid>A819044063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-8f210c097fe10065e8ff4c165f2e721cffeed51fd250d32cb3d3f3284edc4df3</originalsourceid><addsrcrecordid>eNqNk91qFDEUxwdRbK2-gWhAEAV3TSbziReyFK2rCxUt3oZscjKbMpuMScbal_FZPbvdlq70QuYimeR3_ufkfGTZU0anjNfs7bkfg5P9dPAOppSzoqD1veyQtTyfVDnl92_tD7JHMZ5TWvKmqh5mB7yteNWy4jD788X5ix50B2-ITMmmUUPErdNkCFIlqyCS5C9k0LiugIwRiDfkZPF1wkgABUPygcjOOxtTJAZ_LsB2q0R6HyORa--6rWEHDoLsyeCHsZfJekesI5990NK9IzOiAvKTCGpzhVzEUC4fZw-M7CM82a1H2dnHD2fHnyaL05P58WwxUWVepUljckYVbWsDjNKqhMaYQrGqNDnUOVPGAOiSGZ2XVPNcLbnmhudNAVoV2vCj7PmV7IBBi11mo8CkMt7QoqmRmF8R2stzMQS7luFSeGnF9sCHTsiA2epB1MuiZo2GHEtSlJq3eVHIJaMSfZVcStR6v_M2LtcYAbiEidkT3b9xdiU6_0swhsUsqgYVXu0Ugv85QkxibaOCvpcO_LgNvCo5bVmO6It_0Luft6M6iS-wznh0rDaiYtawlmJzVRyp6R0UfhrWVmEfGovnewav9wyQSfA7dXKMUcy_f_t_9vTHPvvyFrsC2adV9P24aZ24DxZX4La7ApibLDMqNmN0nQ2xGSOxGyM0e3a7QjdG13PD_wJOExmc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3141380487</pqid></control><display><type>article</type><title>Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Abutaima, Rana ; Barakat, Muna ; Sawan, Hana M ; Al Omari, Shatha M ; Mhaidat, Nizar M</creator><creatorcontrib>Abutaima, Rana ; Barakat, Muna ; Sawan, Hana M ; Al Omari, Shatha M ; Mhaidat, Nizar M</creatorcontrib><description>Obesity has emerged as a global pandemic, with its prevalence notably increasing during the COVID-19 lockdown of 2019. In response, many individuals have turned to pharmacological interventions, including antidiabetic medications, as means of achieving weight loss with minimal effort. This study aims to assess the knowledge, attitudes, and practices of the Jordanian population regarding the use of antidiabetic agents, specifically glucagon-like peptide-1 receptor agonists and biguanides, for weight management.
A self-administered validated online questionnaire was developed and disseminated to public utilizing a cross-sectional design. Data were extracted to examine descriptive statistics. Linear regression was performed to evaluate associations with knowledge and attitude. A p-value ≤0.05 was chosen to indicate statistical significance.
Total of 389 responses were analyzed, 65.6% females, 54.2% married, 78.1% living in the center of Jordan, 35.5% overweight and 26.5% have >1000 Jordanian Dinars monthly income. Fifty seven percent of the study participants think that antidiabetics could be used for weight loss. 47.27%, 44.55%, 68.18% recognized glucagon-like peptide-1receptor agonists; (Ozempic®), (Saxenda®), (Mounjaro®) as well as (Glucophage®) use for weight loss, respectively and 12.3% of participants used medications to lose weight. Neutral attitude was observed. Gender and body mass index were significantly affecting the participants knowledge (p<0.001, p = 0.002, respectively).
Use of (Ozempic®), (Saxenda®) and other antidiabetics to lose weight become a common practice. The results of this study suggests supervising prescription and dispensing to avoid misuse, especially, in people who are contraindicated to use them.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0314407</identifier><identifier>PMID: 39636914</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Aged ; Agonists ; Analysis ; Antidiabetics ; Attitudes ; Biology and Life Sciences ; Body mass index ; Body size ; Body weight ; Body weight loss ; Cardiovascular disease ; Chronic illnesses ; Computer and Information Sciences ; COVID-19 ; COVID-19 - epidemiology ; Cross-Sectional Studies ; Diabetes ; Diabetes mellitus ; Epidemics ; FDA approval ; Female ; Gastrointestinal surgery ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Glucagon-Like Peptide-1 Receptor - agonists ; Health aspects ; Health Knowledge, Attitudes, Practice ; Humans ; Hypertension ; Hypoglycemic Agents - therapeutic use ; Jordan ; Kidney diseases ; Liraglutide ; Male ; Males ; Medicine and Health Sciences ; Methods ; Middle Aged ; Obesity ; Obesity - drug therapy ; Obesity - epidemiology ; Pandemics ; Pharmacy ; Population ; Population (statistical) ; Population studies ; Questionnaires ; Receptors ; Research and Analysis Methods ; Social networks ; Social Sciences ; Statistical analysis ; Surveys ; Surveys and Questionnaires ; United States ; Validity ; Weight control ; Weight loss ; Weight Loss - drug effects ; Young Adult</subject><ispartof>PloS one, 2024-12, Vol.19 (12), p.e0314407</ispartof><rights>Copyright: © 2024 Abutaima et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2024 Public Library of Science</rights><rights>2024 Abutaima et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 Abutaima et al 2024 Abutaima et al</rights><rights>2024 Abutaima et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c526t-8f210c097fe10065e8ff4c165f2e721cffeed51fd250d32cb3d3f3284edc4df3</cites><orcidid>0000-0003-1218-0638 ; 0000-0002-7966-1172</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620468/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620468/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39636914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abutaima, Rana</creatorcontrib><creatorcontrib>Barakat, Muna</creatorcontrib><creatorcontrib>Sawan, Hana M</creatorcontrib><creatorcontrib>Al Omari, Shatha M</creatorcontrib><creatorcontrib>Mhaidat, Nizar M</creatorcontrib><title>Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Obesity has emerged as a global pandemic, with its prevalence notably increasing during the COVID-19 lockdown of 2019. In response, many individuals have turned to pharmacological interventions, including antidiabetic medications, as means of achieving weight loss with minimal effort. This study aims to assess the knowledge, attitudes, and practices of the Jordanian population regarding the use of antidiabetic agents, specifically glucagon-like peptide-1 receptor agonists and biguanides, for weight management.
A self-administered validated online questionnaire was developed and disseminated to public utilizing a cross-sectional design. Data were extracted to examine descriptive statistics. Linear regression was performed to evaluate associations with knowledge and attitude. A p-value ≤0.05 was chosen to indicate statistical significance.
Total of 389 responses were analyzed, 65.6% females, 54.2% married, 78.1% living in the center of Jordan, 35.5% overweight and 26.5% have >1000 Jordanian Dinars monthly income. Fifty seven percent of the study participants think that antidiabetics could be used for weight loss. 47.27%, 44.55%, 68.18% recognized glucagon-like peptide-1receptor agonists; (Ozempic®), (Saxenda®), (Mounjaro®) as well as (Glucophage®) use for weight loss, respectively and 12.3% of participants used medications to lose weight. Neutral attitude was observed. Gender and body mass index were significantly affecting the participants knowledge (p<0.001, p = 0.002, respectively).
Use of (Ozempic®), (Saxenda®) and other antidiabetics to lose weight become a common practice. The results of this study suggests supervising prescription and dispensing to avoid misuse, especially, in people who are contraindicated to use them.</description><subject>Adult</subject><subject>Aged</subject><subject>Agonists</subject><subject>Analysis</subject><subject>Antidiabetics</subject><subject>Attitudes</subject><subject>Biology and Life Sciences</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Cardiovascular disease</subject><subject>Chronic illnesses</subject><subject>Computer and Information Sciences</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>Cross-Sectional Studies</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Epidemics</subject><subject>FDA approval</subject><subject>Female</subject><subject>Gastrointestinal surgery</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucagon-Like Peptide-1 Receptor - agonists</subject><subject>Health aspects</subject><subject>Health Knowledge, Attitudes, Practice</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Jordan</subject><subject>Kidney diseases</subject><subject>Liraglutide</subject><subject>Male</subject><subject>Males</subject><subject>Medicine and Health Sciences</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Obesity - epidemiology</subject><subject>Pandemics</subject><subject>Pharmacy</subject><subject>Population</subject><subject>Population (statistical)</subject><subject>Population studies</subject><subject>Questionnaires</subject><subject>Receptors</subject><subject>Research and Analysis Methods</subject><subject>Social networks</subject><subject>Social Sciences</subject><subject>Statistical analysis</subject><subject>Surveys</subject><subject>Surveys and Questionnaires</subject><subject>United States</subject><subject>Validity</subject><subject>Weight control</subject><subject>Weight loss</subject><subject>Weight Loss - drug effects</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk91qFDEUxwdRbK2-gWhAEAV3TSbziReyFK2rCxUt3oZscjKbMpuMScbal_FZPbvdlq70QuYimeR3_ufkfGTZU0anjNfs7bkfg5P9dPAOppSzoqD1veyQtTyfVDnl92_tD7JHMZ5TWvKmqh5mB7yteNWy4jD788X5ix50B2-ITMmmUUPErdNkCFIlqyCS5C9k0LiugIwRiDfkZPF1wkgABUPygcjOOxtTJAZ_LsB2q0R6HyORa--6rWEHDoLsyeCHsZfJekesI5990NK9IzOiAvKTCGpzhVzEUC4fZw-M7CM82a1H2dnHD2fHnyaL05P58WwxUWVepUljckYVbWsDjNKqhMaYQrGqNDnUOVPGAOiSGZ2XVPNcLbnmhudNAVoV2vCj7PmV7IBBi11mo8CkMt7QoqmRmF8R2stzMQS7luFSeGnF9sCHTsiA2epB1MuiZo2GHEtSlJq3eVHIJaMSfZVcStR6v_M2LtcYAbiEidkT3b9xdiU6_0swhsUsqgYVXu0Ugv85QkxibaOCvpcO_LgNvCo5bVmO6It_0Luft6M6iS-wznh0rDaiYtawlmJzVRyp6R0UfhrWVmEfGovnewav9wyQSfA7dXKMUcy_f_t_9vTHPvvyFrsC2adV9P24aZ24DxZX4La7ApibLDMqNmN0nQ2xGSOxGyM0e3a7QjdG13PD_wJOExmc</recordid><startdate>20241205</startdate><enddate>20241205</enddate><creator>Abutaima, Rana</creator><creator>Barakat, Muna</creator><creator>Sawan, Hana M</creator><creator>Al Omari, Shatha M</creator><creator>Mhaidat, Nizar M</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1218-0638</orcidid><orcidid>https://orcid.org/0000-0002-7966-1172</orcidid></search><sort><creationdate>20241205</creationdate><title>Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study</title><author>Abutaima, Rana ; Barakat, Muna ; Sawan, Hana M ; Al Omari, Shatha M ; Mhaidat, Nizar M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-8f210c097fe10065e8ff4c165f2e721cffeed51fd250d32cb3d3f3284edc4df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Agonists</topic><topic>Analysis</topic><topic>Antidiabetics</topic><topic>Attitudes</topic><topic>Biology and Life Sciences</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Cardiovascular disease</topic><topic>Chronic illnesses</topic><topic>Computer and Information Sciences</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>Cross-Sectional Studies</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Epidemics</topic><topic>FDA approval</topic><topic>Female</topic><topic>Gastrointestinal surgery</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucagon-Like Peptide-1 Receptor - agonists</topic><topic>Health aspects</topic><topic>Health Knowledge, Attitudes, Practice</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Jordan</topic><topic>Kidney diseases</topic><topic>Liraglutide</topic><topic>Male</topic><topic>Males</topic><topic>Medicine and Health Sciences</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Obesity - epidemiology</topic><topic>Pandemics</topic><topic>Pharmacy</topic><topic>Population</topic><topic>Population (statistical)</topic><topic>Population studies</topic><topic>Questionnaires</topic><topic>Receptors</topic><topic>Research and Analysis Methods</topic><topic>Social networks</topic><topic>Social Sciences</topic><topic>Statistical analysis</topic><topic>Surveys</topic><topic>Surveys and Questionnaires</topic><topic>United States</topic><topic>Validity</topic><topic>Weight control</topic><topic>Weight loss</topic><topic>Weight Loss - drug effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abutaima, Rana</creatorcontrib><creatorcontrib>Barakat, Muna</creatorcontrib><creatorcontrib>Sawan, Hana M</creatorcontrib><creatorcontrib>Al Omari, Shatha M</creatorcontrib><creatorcontrib>Mhaidat, Nizar M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abutaima, Rana</au><au>Barakat, Muna</au><au>Sawan, Hana M</au><au>Al Omari, Shatha M</au><au>Mhaidat, Nizar M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2024-12-05</date><risdate>2024</risdate><volume>19</volume><issue>12</issue><spage>e0314407</spage><pages>e0314407-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Obesity has emerged as a global pandemic, with its prevalence notably increasing during the COVID-19 lockdown of 2019. In response, many individuals have turned to pharmacological interventions, including antidiabetic medications, as means of achieving weight loss with minimal effort. This study aims to assess the knowledge, attitudes, and practices of the Jordanian population regarding the use of antidiabetic agents, specifically glucagon-like peptide-1 receptor agonists and biguanides, for weight management.
A self-administered validated online questionnaire was developed and disseminated to public utilizing a cross-sectional design. Data were extracted to examine descriptive statistics. Linear regression was performed to evaluate associations with knowledge and attitude. A p-value ≤0.05 was chosen to indicate statistical significance.
Total of 389 responses were analyzed, 65.6% females, 54.2% married, 78.1% living in the center of Jordan, 35.5% overweight and 26.5% have >1000 Jordanian Dinars monthly income. Fifty seven percent of the study participants think that antidiabetics could be used for weight loss. 47.27%, 44.55%, 68.18% recognized glucagon-like peptide-1receptor agonists; (Ozempic®), (Saxenda®), (Mounjaro®) as well as (Glucophage®) use for weight loss, respectively and 12.3% of participants used medications to lose weight. Neutral attitude was observed. Gender and body mass index were significantly affecting the participants knowledge (p<0.001, p = 0.002, respectively).
Use of (Ozempic®), (Saxenda®) and other antidiabetics to lose weight become a common practice. The results of this study suggests supervising prescription and dispensing to avoid misuse, especially, in people who are contraindicated to use them.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>39636914</pmid><doi>10.1371/journal.pone.0314407</doi><tpages>e0314407</tpages><orcidid>https://orcid.org/0000-0003-1218-0638</orcidid><orcidid>https://orcid.org/0000-0002-7966-1172</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2024-12, Vol.19 (12), p.e0314407 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_3141380487 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adult Aged Agonists Analysis Antidiabetics Attitudes Biology and Life Sciences Body mass index Body size Body weight Body weight loss Cardiovascular disease Chronic illnesses Computer and Information Sciences COVID-19 COVID-19 - epidemiology Cross-Sectional Studies Diabetes Diabetes mellitus Epidemics FDA approval Female Gastrointestinal surgery GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Health aspects Health Knowledge, Attitudes, Practice Humans Hypertension Hypoglycemic Agents - therapeutic use Jordan Kidney diseases Liraglutide Male Males Medicine and Health Sciences Methods Middle Aged Obesity Obesity - drug therapy Obesity - epidemiology Pandemics Pharmacy Population Population (statistical) Population studies Questionnaires Receptors Research and Analysis Methods Social networks Social Sciences Statistical analysis Surveys Surveys and Questionnaires United States Validity Weight control Weight loss Weight Loss - drug effects Young Adult |
| title | Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T10%3A11%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Knowledge,%20attitudes,%20and%20practices%20towards%20the%20use%20of%20GLP-1%20receptor%20agonists%20for%20weight%20loss%20among%20the%20general%20population%20in%20Jordan;%20A%20cross-sectional%20study&rft.jtitle=PloS%20one&rft.au=Abutaima,%20Rana&rft.date=2024-12-05&rft.volume=19&rft.issue=12&rft.spage=e0314407&rft.pages=e0314407-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0314407&rft_dat=%3Cgale_plos_%3EA819044063%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3141380487&rft_id=info:pmid/39636914&rft_galeid=A819044063&rft_doaj_id=oai_doaj_org_article_7b4718de214445d39244ab10adc453aa&rfr_iscdi=true |